Low- vs high-dose aspirin. Effects on platelet function in hyperlipoproteinemic and normal subjects

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Hyperlipoproteinemia is associated with increased platelet reactivity.
• The efficacy of low-dose aspirin in inhibiting platelet function in hyperlipoproteinemic individuals remains unclear.

Purpose of the Study:

• To investigate the effect of low-dose aspirin on platelet function in type II hyperlipoproteinemia.
• To compare platelet function inhibition between hyperlipoproteinemic and normal subjects.

Main Methods:

• 18 type II hyperlipoproteinemic and 12 normal subjects participated.
• Platelet function was assessed after treatment with placebo, low-dose aspirin (0.45 mg/kg/day), and high-dose aspirin (900 mg/day).
• Measurements included platelet thromboxane generation, bleeding time, and platelet aggregation.

Main Results:

• Low-dose aspirin achieved near-maximal (90%) inhibition of platelet thromboxane generation in both groups.
• Significant prolongation of bleeding time and inhibition of platelet aggregation were observed with low-dose aspirin.
• No significant differences in platelet function measures were found between hyperlipoproteinemic and normal subjects before or after aspirin treatment.

Conclusions:

• A daily low dose of aspirin (0.45 mg/kg) effectively inhibits platelet function in type II hyperlipoproteinemia.
• Individuals with type II hyperlipoproteinemia do not appear to require a higher aspirin dose for adequate platelet inhibition.